Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2017

  • ID: 4339014
  • Report
  • 137 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AnGes MG Inc
  • C. R. Bard Inc
  • eucatech AG
  • Medtronic plc
  • QT Vascular Ltd
  • SurModics Inc
  • MORE
Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2017" provides an overview of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AnGes MG Inc
  • C. R. Bard Inc
  • eucatech AG
  • Medtronic plc
  • QT Vascular Ltd
  • SurModics Inc
  • MORE
1 Table of Contents
2 Introduction
2.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Overview
3 Products under Development
3.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
3.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
3.3 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
3.4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
3.5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies
4.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
4.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview
5.1 AnGes MG Inc Company Overview
5.1.1 AnGes MG Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 AngioCure, Inc. Company Overview
5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.3 C. R. Bard Inc Company Overview
5.3.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Contego Medical, LLC Company Overview
5.4.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.5 eucatech AG Company Overview
5.5.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
5.6 M.A. Med Alliance SA Company Overview
5.6.1 M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview
5.7 Medtronic plc Company Overview
5.7.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Micell Technologies Inc Company Overview
5.8.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 QT Vascular Ltd Company Overview
5.9.1 QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.10 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.10.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.11 SiL Vascular Ltd Company Overview
5.11.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.12 SurModics Inc Company Overview
5.12.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.13 The Spectranetics Corp Company Overview
5.13.1 The Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview
5.14 Vascular Nanotransfer Technologies Company Overview
5.14.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
6 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB)- Recent Developments
6.1 Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell
6.2 Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced
6.3 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.4 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors
6.5 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund
6.6 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
6.7 May 24, 2017: Medtronic Enrolls First Patient in Study of IN.PACT AV Access Drug-Coated Balloon in Patients with End-Stage Renal Disease
6.8 May 03, 2017: Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results
6.9 Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
6.10 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
6.11 Apr 27, 2017: Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance
6.12 Apr 27, 2017: Spectranetics Reports First Quarter 2017 Revenue of $69.7 million
6.13 Apr 25, 2017: Medtronic Drug-Coated Balloon Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients
6.14 Apr 23, 2017: Bard Announces First Quarter Results
6.15 Apr 17, 2017: Surmodics Appoints Lisa Wipperman Heine to Its Board of Directors
6.16 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board
6.17 Mar 31, 2017: B. Braun continues its sales and earnings growth
6.18 Mar 24, 2017: LifeTech Announces 2016 Annual Results
6.19 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech
6.20 Mar 09, 2017: Medtronic Launches Below-The-Knee Clinical Study In Europe For Treatment Of PAD Using New Drug-Coated Balloon Technology
6.21 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia
6.22 Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017
6.23 Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers
6.24 Feb 23, 2017: Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million
6.25 Feb 22, 2017: Change in the B. Braun Management Board
6.26 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
6.27 Feb 21, 2017: Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors
6.28 Feb 20, 2017: LUMINOR Registry may help “reopen the door” for drug-coated balloons below the knee
6.29 Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha
6.30 Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure
6.31 Feb 09, 2017: Medtronic Announces Health Canada Licence for Drug-Coated Balloon
6.32 Feb 09, 2017: First Drug-Coated Balloon Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies
6.33 Feb 09, 2017: Terumo Announces Change of Executive Officers
6.34 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
6.35 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
6.36 Feb 02, 2017: Surmodics Reports First Quarter Fiscal 2017 Results
6.37 Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President
6.38 Jan 31, 2017: Terumo Opens a Branch in Yangon
6.41 Jan 25, 2017: Medtronic IN.PACT Admiral Drug-Coated Balloon Demonstrates Consistent Results in Asia and Belgium According to New Data Presented at LINC 2017
6.42 Jan 25, 2017: LINC 2017: Physicians Discuss Lesion Response-Adapted Therapies for Lower Limb Interventions
6.43 Jan 25, 2017: iVascular Official Program Activities at LINC 2017
6.44 Jan 25, 2017: Cardiovascular Systems Reports Fiscal 2017 Second-Quarter Financial Results
6.45 Jan 24, 2017: ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations
6.46 Jan 11, 2017: Spectranetics Names Scott Hutton as General Manager, Vascular Intervention
6.47 Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System
6.48 Dec 16, 2016: FDA Grants QT Vascular Full IDE Approval to Begin Pivotal Trial Of Its Drug-Coated Balloon, Chocolate Touch
6.49 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy
6.50 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
6.51 Nov 21, 2016: Spectranetics Receives CE Mark for Stellarex 0.014” Drug-Coated Balloon
6.52 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
6.53 Nov 16, 2016: Surmodics Reports Fourth Quarter Fiscal 2016 Results
6.54 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction
6.55 Nov 02, 2016: Spectranetics Files PMA Application for FDA Approval of the Stellarex Drug-Coated Balloon
6.56 Nov 02, 2016: Stellarex ILLUMENATE Pivotal Results Are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials
6.57 Oct 31, 2016: Surmodics Announces Launch of Serene Single-Coat (SC) Solutions Offering Unmatched Lubricity and Durability to a Broader Range of Device Applications
6.58 Oct 27, 2016: Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million
6.59 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
6.60 Oct 26, 2016: Cardiovascular Systems Reports Fiscal 2017 First-Quarter Financial Results
6.61 Oct 25, 2016: Bard Announces Third Quarter Results
6.62 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
6.63 Sep 19, 2016: QT Vascular Announces FDA Has Granted Approval To Initiate The Pivotal Trial Of Its Novel Drug-Coated Balloon
6.64 Sep 19, 2016: New Data Presented in VIVA Late Breaking Clinical Trials Demonstrate Durability, Safety and Efficacy for the Medtronic In.Pact Admiral DCB
6.65 Sep 19, 2016: FDA Approves 6-Month Primary End Point For The Lutonix Below-the-Knee Drug Coated Balloon
6.66 Sep 15, 2016: Eurocor enters the market with their FREEWAY COATED SHUNT BALLOON CATHETER
6.67 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
6.68 Sep 13, 2016: Medtronic Receives FDA Approval of First Drug-Coated Balloon for Treatment of In-Stent Restenosis
6.69 Sep 06, 2016: Daiichi Sankyo Announces New Global Head of Development
6.70 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China
6.71 Aug 25, 2016: Medtronic Reports First Quarter Financial Results
6.72 Aug 16, 2016: Cardiovascular Systems Names Scott Ward as CEO
6.73 Aug 10, 2016: First Randomized Trial of the Stellarex Drug-coated Balloon Presented at the Amputation Prevention Symposium
6.74 Aug 03, 2016: Cardiovascular Systems Reports Fiscal 2016 Fourth-Quarter Financial Results
6.75 Jul 28, 2016: Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million
6.76 Jul 28, 2016: Surmodics Reports Third Quarter Fiscal 2016 Results
6.77 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
6.78 Jul 26, 2016: Bard Announces Second Quarter Results
6.79 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment
6.80 Jul 21, 2016: Federal Circuit Court Rules in Appeal
6.81 Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Table 3: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Table 4: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Table 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
Table 6: PTA Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
Table 7: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 8: AnGes MG Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status
Table 10: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description
Table 11: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 12: AngioCure TOP-C Smart Balloon Catheter - Product Status
Table 13: AngioCure TOP-C Smart Balloon Catheter - Product Description
Table 14: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Lutonix - AV - Product Status
Table 16: Lutonix - AV - Product Description
Table 17: Lutonix - ISR - Product Status
Table 18: Lutonix - ISR - Product Description
Table 19: Lutonix 014 DCB Catheter - Product Status
Table 20: Lutonix 014 DCB Catheter - Product Description
Table 21: C. R. Bard Inc - Ongoing Clinical Trials Overview
Table 22: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry)
Table 23: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Arm Real-world Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) Catheter for Treatment of Below-the-Knee (BTK) Arteries
Table 24: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-knee (BTK) Arteries (Lutonix BTK Trial)
Table 25: Lutonix 014 DCB Catheter - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix
Table 26: Lutonix 014 DCB Catheter - Evaluation of Paclitaxel in Patients with CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated with DCB Angioplasty
Table 27: Lutonix 014 DCB Catheter - Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System
Table 28: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Tibial Artery Drug Eluting Balloon - Product Status
Table 30: Tibial Artery Drug Eluting Balloon - Product Description
Table 31: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Support - Product Status
Table 33: Support - Product Description
Table 34: M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview
Table 35: SELUTION Sirolimus Coated Balloon - Product Status
Table 36: SELUTION Sirolimus Coated Balloon - Product Description
Table 37: M.A. Med Alliance SA - Ongoing Clinical Trials Overview
Table 38: SELUTION Sirolimus Coated Balloon - SELUTION Sirolimus Coated PTA Balloon Catheter Prospective, Controlled, Multi-center, Open, Single-arm Clinical Investigation for the Treatment of Patients with Femoropopliteal Artery Lesions with a Novel Drug Coated Balloon
Table 39: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
Table 40: IN.PACT Admiral DEB - BTK - Product Status
Table 41: IN.PACT Admiral DEB - BTK - Product Description
Table 42: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Product Status
Table 43: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Product Description
Table 44: IN.PACT AV Access Drug-Coated Balloon - 8 -12mm - Product Status
Table 45: IN.PACT AV Access Drug-Coated Balloon - 8 -12mm - Product Description
Table 46: Medtronic plc - Ongoing Clinical Trials Overview
Table 47: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Study of IN.PACT Admiral Drug-coated Balloon for a New Indication in Subjects with End-stage Renal Disease
Table 48: IN.PACT Admiral DEB - BTK - Randomized Study of IN.PACT 014 Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Chronic Total Occlusions in the Infrapopliteal Arteries
Table 49: Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Drug-Coated Balloon - Product Status
Table 51: Drug-Coated Balloon - Product Description
Table 52: QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Chocolate Touch - Product Status
Table 54: Chocolate Touch - Product Description
Table 55: QT Vascular Ltd - Ongoing Clinical Trials Overview
Table 56: Chocolate Touch - A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions
Table 57: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status
Table 59: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description
Table 60: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Peripheral Vascular Balloon - Product Status
Table 62: Peripheral Vascular Balloon - Product Description
Table 63: SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 64: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status
Table 65: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description
Table 66: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status
Table 67: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description
Table 68: SurVeil Drug Coated Balloon - SFA - Product Status
Table 69: SurVeil Drug Coated Balloon - SFA - Product Description
Table 70: SurModics Inc - Ongoing Clinical Trials Overview
Table 71: SurVeil Drug Coated Balloon - SFA - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery
Table 72: The Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Stellarex 0.014” Drug-Coated Balloon - Below The Knee (BTK) - Product Status
Table 74: Stellarex 0.014” Drug-Coated Balloon - Below The Knee (BTK) - Product Description
Table 75: Stellarex Drug Coated Balloon - Above-The-Knee - Product Status
Table 76: Stellarex Drug Coated Balloon - Above-The-Knee - Product Description
Table 77: The Spectranetics Corp - Ongoing Clinical Trials Overview
Table 78: Stellarex Drug Coated Balloon - Above-The-Knee - Economic Evaluation Comparing Standard Balloon Angioplasty Versus Drug-eluted Balloon or Laser-excimer in Association with Drug-eluted Balloon in the Treatment of Femoropopliteal Artery In-stent Restenosis
Table 79: Stellarex Drug Coated Balloon - Above-The-Knee - Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting with De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter
Table 80: Stellarex Drug Coated Balloon - Above-The-Knee - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery (SFA) and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty (PTA) Balloon and in In-Stent Restenosis (ILLUMENATE GLOBAL and ISR)
Table 81: Stellarex Drug Coated Balloon - Above-The-Knee - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon
Table 82: Stellarex Drug Coated Balloon - Above-The-Knee - Stellarex Vascular E-Registry
Table 83: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
Table 84: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status
Table 85: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description
Table 86: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status
Table 87: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description
Table 88: Glossary

List of Figures
Figure 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Figure 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Figure 3: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Figure 4: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Figure 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AnGes MG Inc
  • AngioCure, Inc.
  • C. R. Bard Inc
  • Contego Medical, LLC
  • eucatech AG
  • M.A. Med Alliance SA
  • Medtronic plc
  • Micell Technologies Inc
  • QT Vascular Ltd
  • QualiMed Innovative Medizinprodukte GmbH
  • SiL Vascular Ltd
  • SurModics Inc
  • The Spectranetics Corp
  • Vascular Nanotransfer Technologies
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll